• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Antidepressants Market to 2018 - Despite Safety Concerns, Selective Serotonin Re-uptake Inhibitors (SSRIs) Continue to Dominate in the Absence of Effective Therapeutic Alternatives - Product Image

Antidepressants Market to 2018 - Despite Safety Concerns, Selective Serotonin Re-uptake Inhibitors (SSRIs) Continue to Dominate in the Absence of Effective Therapeutic Alternatives

  • ID: 2261984
  • October 2012
  • 110 Pages
  • GBI Research

FEATURED COMPANIES

  • AstraZeneca
  • Eli Lilly and Company
  • Forest Laboratories
  • GlaxoSmithKline
  • H. Lundbeck
  • Pfizer Inc.
  • MORE

GBI Research, the leading business intelligence provider, has released its latest research, “Antidepressants Market to 2018 - Despite Safety Concerns, Selective Serotonin Re-uptake Inhibitors (SSRIs) Continue to Dominate in the Absence of Effective Therapeutic Alternatives”, which provides insights into the antidepressants market until 2018.

The report is built using data sourced from our proprietary databases and primary and secondary research, in addition to analysis from our in-house specialized team of experts. The report provides an in-depth analysis of the major antidepressants therapies, including SSRIs, Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Tricyclic Antidepressants (TCAs), covering Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Generalized Anxiety Disorder (GAD) and Panic Disorder (PD). The report provides the sales for the global antidepressant market in addition to the individual indication markets. It also examines the global antidepressant market treatment usage patterns, in addition to the geographical distribution of antidepressants across the US, the top five countries of Europe, and Japan.

The report READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca
  • Eli Lilly and Company
  • Forest Laboratories
  • GlaxoSmithKline
  • H. Lundbeck
  • Pfizer Inc.
  • MORE

1.1 List of Tables
1.2 List of Figures

2 Antidepressants Market to 2018 - Introduction

3 Market Overview
3.1 Introduction
3.2 Classification of Antidepressants
3.2.1 Selective Serotonin Reuptake Inhibitors
3.2.2 Serotonin-Norepinephrine Reuptake Inhibitors
3.2.3 Noradrenergic and Specific Serotonergic Antidepressants
3.2.4 Norepinephrine Reuptake Inhibitors
3.2.5 Norepinephrine-Dopamine Reuptake Inhibitors
3.2.6 Norepinephrine-Dopamine Disinhibitors
3.2.7 Serotonin Antagonist and Reuptake Inhibitors
3.2.8 Tricyclic Antidepressants
3.2.9 Tetracyclic Antidepressants
3.2.10 Monoamine Oxidase Inhibitors
3.2.11 Others
3.3 Adverse Effects
3.4 Major Marketed Products in the Antidepressants Therapy Area
3.5 Future Developments
3.6 Revenue
3.7 Annual Cost of Therapy
3.8 Treatment Usage Patterns
3.8.1 Diseased Population
3.8.2 Diagnosed Population
3.8.3 Prescription Population
3.9 Drivers and Restraints of the Antidepressants Market
3.9.1 Drivers
3.9.2 Restraints

4 Therapeutic Landscape
4.1 Antidepressants Market for Major Depressive Disorder
4.1.1 Introduction
4.1.2 Revenue and Forecasts
4.1.3 Annual Cost of Therapy
4.1.4 Treatment Usage Patterns
4.1.5 Geographical Segmentation
4.2 Drivers and Restraints for the Antidepressants Market for Major Depressive Disorder
4.2.1 Drivers
4.2.2 Restraints
4.3 Antidepressants Market for Obsessive-Compulsive Disorder
4.3.1 Introduction
4.3.2 Revenue and Forecasts
4.3.3 Annual Cost of Therapy
4.3.4 Treatment Usage Patterns
4.3.5 Geographical Segmentation
4.4 Drivers and Restraints for the Antidepressants Market for Obsessive-Compulsive Disorder
4.4.1 Drivers
4.4.2 Restraints
4.5 Antidepressants Market for Generalized Anxiety Disorder
4.5.1 Introduction
4.5.2 Revenue and Forecasts
4.5.3 Annual Cost of Therapy
4.5.4 Treatment Usage Patterns
4.5.5 Geographical Segmentation
4.6 Drivers and Restraints for the Antidepressants Market for Generalized Anxiety Disorder
4.6.1 Drivers
4.6.2 Restraints
4.7 Antidepressants Market for Panic Disorder
4.7.1 Introduction
4.7.2 Revenue and Forecasts
4.7.3 Annual Cost of Therapy
4.7.4 Treatment Usage Patterns
4.7.5 Geographical Segmentation
4.8 Drivers and Restraints for the Antidepressants Market for Panic Disorder
4.8.1 Drivers
4.8.2 Restraints

5 Geographical Landscape
5.1 The US
5.1.1 Revenue and Forecasts
5.1.2 Annual Cost of Therapy
5.1.3 Treatment Usage Patterns
5.2 EU5
5.2.1 Revenue and Forecasts
5.2.2 Annual Cost of Therapy
5.2.3 Treatment Usage Patterns
5.3 Japan
5.3.1 Revenue and Forecasts
5.3.2 Annual Cost of Therapy
5.3.3 Treatment Usage Patterns

6 Pipeline Analysis
6.1 Introduction
6.2 Summary of the Current Antidepressants R&D Pipeline
6.3 Profiles of Key Late-Stage Drugs in the Antidepressants Market
6.3.1 Vortioxetine (Lu AA21004)
6.3.2 F-2695 (levomilnacipran)
6.3.3 LY-2216684 (edivoxetine)
6.3.4 OPC-34712
6.3.5 EB-1010/Amitifadine
6.3.6 PNB01

7 Competitive Landscape
7.1 Competitive Profiling
7.1.1 H. Lundbeck
7.1.2 AstraZeneca
7.1.3 Eli Lilly and Company
7.1.4 Forest Laboratories
7.1.5 Pfizer Inc.
7.1.6 GlaxoSmithKline
7.1.7 Bristol-Myers Squibb Company

8 Strategic Consolidations
8.1 Merger and Acquisition Deals
8.1.1 Paladin Labs Completes Acquisition of Labopharm
8.1.2 High River Acquires 6.5% Stake in Forest Laboratories
8.1.3 Forest Laboratories Completes Acquisition of Clinical Data
8.1.4 Azur Pharma Completes Merger with Jazz Pharmaceuticals in All Stock Transaction
8.1.5 Nuvo Research Acquires ZARS Pharma
8.1.6 Sun Pharmaceutical Acquires Remaining 24% Stake of Caraco Pharmaceutical
8.2 Licensing Agreements
8.2.1 Labopharm Enters into Licensing Agreement with Angelini Group for OLEPTRO
8.2.2 Omeros Expands Licensing Agreement with Daiichi Sankyo
8.2.3 Jazz Pharmaceuticals Enters into Sub-Licensing Agreement with Anchen
8.2.4 AstraZeneca Enters into Collaboration and Licensing Agreement with Targacept
8.2.5 Indevus Pharmaceuticals Enters into Licensing Agreement with Teva Pharmaceutical
8.2.6 Impax Laboratories Enters into Licensing Agreement with Wyeth
8.2.7 Mylan Enters into Licensing Agreement with GlaxoSmithKline
8.2.8 Tikvah Therapeutics Signs Licensing Agreement with Therapade Technologies
8.2.9 GlaxoSmithKline Signs an Agreement with Fabre-Kramer Pharmaceuticals
8.2.10 Jazz Pharmaceuticals Enters into Licensing Agreement with Solvay
8.2.11 Targacept Enters into Licensing Agreement with Yale University
8.3 Co-Development Deals
8.3.1 Lundbeck Enters into Co-Development Agreement with Otsuka Pharmaceutical
8.3.2 Eli Lilly Terminates Co-Development Agreement with Boehringer Ingelheim
8.3.3 Lundbeck Enters into Co-Development Agreement with Takeda

9 Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Sources
9.4 Research Methodology
9.4.1 Coverage
9.4.2 Secondary Research
9.4.3 Primary Research
9.5 Therapeutic Landscape
9.5.1 Epidemiology-based Forecasting
9.5.2 Market Size by Geography
9.6 Geographical Landscape
9.7 Pipeline Analysis
9.8 Competitive Landscape
9.8.1 Expert Panel Validation
9.9 Contact Us
9.10 Disclaimer

1.1 List of Tables

Table 1: Global Antidepressants Market, Marketed Products, 2012
Table 2: Antidepressants Market, Global, Revenue ($bn), 2004–2011
Table 3: Antidepressants Market, Global, Revenue Forecast ($bn), 2011–2018
Table 4: Antidepressants Market, Global, Annual Cost of Therapy ($), 2004–2011
Table 5: Antidepressants Market, Global, Annual Cost of Therapy ($), 2011–2018
Table 6: Antidepressants Market, Global, Treatment Usage Patterns (millions), 2004–2011
Table 7: Antidepressants Market, Global, Treatment Usage Patterns (millions), 2011–2018
Table 8: Antidepressants Market, MDD, Global, Revenue ($bn), 2004–2011
Table 9: Antidepressants Market, MDD, Global, Revenue Forecast ($bn), 2011–2018
Table 10: Antidepressants Market, MDD, Global, Annual Cost of Therapy ($), 2004–2011
Table 11: Antidepressants Market, MDD, Global, Annual Cost of Therapy ($), 2011–2018
Table 12: Antidepressants Market, MDD, Global, Treatment Usage Patterns (millions), 2004–2011
Table 13: Antidepressants Market, MDD, Global, Treatment Usage Patterns (millions), 2011–2018
Table 14: Antidepressants Market, MDD, Global, Market Segmentation by Geography ($bn), 2004–2011
Table 15: Antidepressants Market, MDD, Global, Market Segmentation by Geography ($bn), 2011–2018
Table 16: Common Obsessions and Compulsions in Obsessive-Compulsive Disorder
Table 17: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Revenue ($bn), 2004–2011
Table 18: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Revenue Forecast ($bn), 2011–2018
Table 19: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Annual Cost of Therapy ($), 2004–2011
Table 20: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Annual Cost of Therapy ($), 2011–2018
Table 21: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Treatment Usage Patterns (millions), 2004–2011
Table 22: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Treatment Usage Patterns (millions), 2011–2018
Table 23: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Market Segmentation by Geography ($m), 2004–2011
Table 24: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Market Segmentation by Geography ($m), 2011–2018
Table 25: Antidepressants Market, Generalized Anxiety Disorder, Global, Revenue ($bn), 2004–2011
Table 26: Antidepressants Market, Generalized Anxiety Disorder, Global, Revenue Forecast ($bn), 2011–2018
Table 27: Antidepressants Market, Generalized Anxiety Disorder, Global, Annual Cost of Therapy ($), 2004–2011
Table 28: Antidepressants Market, Generalized Anxiety Disorder, Global, Annual Cost of Therapy ($), 2011–2018
Table 29: Antidepressants Market, Generalized Anxiety Disorder, Global, Treatment Usage Patterns (millions), 2004–2011
Table 30: Antidepressants Market, Generalized Anxiety Disorder, Global, Treatment Usage Patterns (millions), 2011–2018
Table 31: Antidepressants Market, Generalized Anxiety Disorder, Global, Market Segmentation by Geography ($m), 2004–2011
Table 32: Antidepressants Market, Generalized Anxiety Disorder, Global, Market Segmentation by Geography ($m), 2011–2018
Table 33: Antidepressants Market, Panic Disorder, Global, Revenue ($m), 2004–2011
Table 34: Antidepressants Market, Panic Disorder, Global, Revenue ($m), 2011–2018
Table 35: Antidepressants Market, Panic Disorder, Global, Annual Cost of Therapy ($), 2004–2011
Table 36: Antidepressants Market, Panic Disorder, Global, Annual Cost of Therapy ($), 2011–2018
Table 37: Antidepressants Market, Panic Disorder, Global, Treatment Usage Patterns (millions), 2004–2011
Table 38: Antidepressants Market, Panic Disorder, Global, Treatment Usage Patterns (millions), 2011–2018
Table 39: Antidepressants Market, Panic Disorder, Global, Market Segmentation by Geography ($m), 2004–2011
Table 40: Antidepressants Market, Panic Disorder, Global, Market Segmentation by Geography ($m), 2011–2018
Table 41: Antidepressants Market, Global, Revenues by Geography ($bn), 2004–2011
Table 42: Antidepressants Market, Global, Revenues by Geography ($bn), 2011–2018
Table 43: Antidepressants Market, The US, Revenue ($bn), 2004–2011
Table 44: Antidepressants Market, The US, Revenue Forecast ($bn), 2011–2018
Table 45: Antidepressants Market, The US, Annual Cost of Therapy ($), 2004–2011
Table 46: Antidepressants Market, The US, Annual Cost of Therapy ($), 2011–2018
Table 47: Antidepressants Market, The US, Treatment Usage Patterns (millions), 2004–2011
Table 48: Antidepressants Market, The US, Treatment Usage Patterns (millions), 2011–2018
Table 49: Antidepressants Market, EU5, Revenue ($bn), 2004–2011
Table 50: Antidepressants Market, EU5, Revenue Forecast ($bn), 2011–2018
Table 51: Antidepressants Market, EU5, Annual Cost of Therapy ($), 2004–2011
Table 52: Antidepressants Market, EU5, Annual Cost of Therapy ($), 2011–2018
Table 53: Antidepressants Market, EU5, Treatment Usage Patterns (millions), 2004–2011
Table 54: Antidepressants Market, EU5, Treatment Usage Patterns (millions), 2011–2018
Table 55: Antidepressants Market, Japan, Revenue ($m), 2004–2011
Table 56: Antidepressants Market, Japan, Revenue ($m), 2011–2018
Table 57: Antidepressants Market, Japan, Annual Cost of Therapy ($), 2004–2011
Table 58: Antidepressants Market, Japan, Annual Cost of Therapy ($), 2011–2018
Table 59: Antidepressants Market, Japan, Treatment Usage Patterns (millions), 2004–2011
Table 60: Antidepressants Market, Japan, Treatment Usage Patterns (millions), 2011–2018
Table 61: Antidepressants Market, Pipeline, 2012
Table 62: Lundbeck, Antidepressant Pipeline Products, 2011
Table 63: AstraZeneca, Antidepressants Pipeline, 2011
Table 64: Eli Lilly and Company, Antidepressants Pipeline, 2011
Table 65: Forest Laboratories, MDD, Pipeline Products, 2011

1.2 List of Figures

Figure 1: Antidepressants Market, Global, Revenue ($bn), 2004–2018
Figure 2: Antidepressants Market, Global, Annual Cost of Therapy ($), 2004–2018
Figure 3: Antidepressants Market, Global, Therapeutic Usage Patterns (millions), 2004–2018
Figure 4: Antidepressants Market, MDD, Global, Revenue ($bn), 2004–2018
Figure 5: Antidepressants Market, MDD, Global, Annual Cost of Therapy ($), 2004–2018
Figure 6: Antidepressants Market, MDD, Global, Treatment Usage Patterns (millions), 2004–2018
Figure 7: Antidepressants Market, MDD, Global, Market Segmentation by Geography ($bn), 2004–2018
Figure 8: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Revenue ($bn), 2004–2018
Figure 9: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Annual Cost of Therapy ($), 2004–2018
Figure 10: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Treatment Usage Patterns (millions), 2004–2018
Figure 11: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Market Segmentation by Geography ($m), 2004–2018
Figure 12: Antidepressants Market, Generalized Anxiety Disorder, Global, Revenue ($bn), 2004–2018
Figure 13: Antidepressants Market, Generalized Anxiety Disorder, Global, Annual Cost of Therapy ($), 2004–2018
Figure 14: Antidepressants Market, Generalized Anxiety Disorder, Global, Treatment Usage Patterns (millions), 2004–2018
Figure 15: Antidepressants Market, Generalized Anxiety Disorder, Global, Market Segmentation by Geography ($m), 2004–2018
Figure 16: Antidepressants Market, Panic Disorder, Global, Revenue ($m), 2004–2018
Figure 17: Antidepressants Market, Panic Disorder, Global, Annual Cost of Therapy ($), 2004–2018
Figure 18: Antidepressants Market, Panic Disorder, Global, Treatment Usage Patterns (millions), 2004–2018
Figure 19: Antidepressants Market, Panic Disorder, Global, Market Segmentation by Geography ($m), 2004–2018
Figure 20: Antidepressants Market, Global, Revenues by Geography ($bn), 2004–2018
Figure 21: Antidepressants Market, The US, Revenue ($bn), 2004–2018
Figure 22: Antidepressants Market, The US, Annual Cost of Therapy ($), 2004–2018
Figure 23: Antidepressants Market, The US, Treatment Usage Patterns (millions), 2004–2018
Figure 24: Antidepressants Market, EU5, Revenue ($bn), 2004–2018
Figure 25: Antidepressants Market, EU5, Annual Cost of Therapy ($), 2004–2018
Figure 26: Antidepressants Market, EU5, Treatment Usage Patterns (millions), 2004–2018
Figure 27: Antidepressants Market, Japan, Revenue ($m), 2004–2018
Figure 28: Antidepressants Market, Japan, Annual Cost of Therapy ($), 2004–2018
Figure 29: Antidepressants Market, Japan, Treatment Usage Patterns (millions), 2004–2018
Figure 30: Antidepressants Market, SWOT Analysis, Lundbeck, 2011
Figure 31: Antidepressants Market, SWOT Analysis, AstraZeneca, 2011
Figure 32: Antidepressants Market, SWOT Analysis, Eli Lilly and Company, 2011
Figure 33: Antidepressants Market, SWOT Analysis, Forest Laboratories, 2011
Figure 34: Antidepressants Market, SWOT Analysis, Pfizer Inc., 2011
Figure 35: Antidepressants Market, SWOT Analysis, GlaxoSmithKline, 2011
Figure 36: Antidepressants Market, SWOT Analysis, Bristol-Myers Squibb, 2011
Figure 37: GBI Research Market Forecasting Model

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca
  • Eli Lilly and Company
  • Forest Laboratories
  • GlaxoSmithKline
  • H. Lundbeck
  • Pfizer Inc.
  • MORE

Considerable Scope for Improvement’ in Antidepressants Market, Says Report

Further research into the disease etiology of a number of mental health disorders would open up considerable scope for improvement in the development of antidepressants, says a new report by GBI Research.

The report* states that the global antidepressants market for Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Generalized Anxiety Disorder (GAD) and Panic Disorder (PD) – estimated at $11.9 billion in 2011 – is forecast to generate $13.4 billion by 2018. Antidepressants are among the top three most prescribed classes of drugs in the US, along with cholesterol-lowering drugs and painkillers.

The report states that Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) are the most commonly prescribed classes of antidepressants, but many patients fail to respond adequately to them, while a significant number of patients also discontinue therapy due to negative and unwanted side effects.

Latency is also a factor in drug compliance, as the positive effects of antidepressants may only be seen after around six weeks, leading to more instances of treatment discontinuance due to frustration and lost confidence in the drug. The report estimates that around 25% of patients will stop taking their prescribed medication within the first four weeks of treatment.

The pharmaceutical industry has so far struggled to improve on current antidepressants, partly due to inadequate understanding and the difficulty of conducting clinical trials, according to GBI Research analysis. A notably high placebo effect, and a lack of objective assessment criteria and financing all represent drawbacks for scientific study into antidepressant therapeutics.

Without major breakthroughs in scientific understanding, development activity in this therapeutic area will be restricted. However, this does leave considerable scope for improvement over the current treatment options if understanding of the disease etiology improves.

* Antidepressants Market to 2018 - Despite Safety Concerns, Selective Serotonin Re-uptake Inhibitors (SSRIs) Continue to Dominate in the Absence of Effective Therapeutic Alternatives

This report provides an in-depth analysis of the major antidepressants therapies, including SSRIs, Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Tricyclic Antidepressants (TCAs), covering Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Generalized Anxiety Disorder (GAD) and Panic Disorder (PD). It provides the sales, treatment usage patterns for the global antidepressant market in addition to the individual indication markets. It also provides the geographical distribution of antidepressants across the US, the top five countries of Europe, and Japan, and gives insights into the antidepressants R&D product pipeline and explores the competitive landscape, including major players in the antidepressants market. Finally, the report also includes analysis on the Mergers and Acquisitions (M&As) and licensing agreements that took place in antidepressant market.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Note: Product cover images may vary from those shown

- H. Lundbeck
- AstraZeneca
- Eli Lilly and Company
- Forest Laboratories
- Pfizer Inc.
- GlaxoSmithKline
- Bristol-Myers Squibb Company

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos